Scandinavian Biopharma is once again looking back on a very successful business year
Scandinavian Biopharma can look back on a very successful 2019! The company was granted 10.6 MEUR from the EDCTP for a phase III trial of the ETEC vaccine candidate ETVAX® in children in Low- and Middle-Income Countries (LMIC). Impressive clinical results from Phase I/II study in Bangladesh were published. A late phase African paediatric development […]
